Searchable abstracts of presentations at key conferences in endocrinology

ea0014p105 | (1) | ECE2007

Echo-enhanced ultrasound has a higher sensitivity than high-resolution CT in the detection of hepatic metastasis of adrenocortical carcinoma

Bauditz Jürgen , Wermke Wolfram , Beyersdorff Dirk , Lochs Herbert , Strasburger Christian J. , Quinkler Marcus

Background: Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with incompletely understood pathogenesis and poor prognosis. Computerized tomography (CT) and magnetic resonance imaging (MRI) are routinely performed for imaging of the adrenal mass and for standard staging of chest and abdomen as lung and liver are the primary organs for metastatic spread in ACC. Contrast ultrasound is a non-invasive procedure which has been shown to have a high sensitivity an...

ea0014oc10.2 | Obesity & metabolism | ECE2007

11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) mRNA expression in liver of patients with non-alcoholic steatohepatitis

Konopelska Sarah , Kienitz Tina , Pirlich Matthias , Bauditz Jürgen , Stewart Paul M. , Lochs Herbert , Strasburger Christian J. , Quinkler Marcus

Background: Non-alcoholic fatty liver disease (NAFLD) is recognized as common liver disorder that represents the hepatic manifestation of the metabolic syndrome including visceral obesity, type 2 diabetes, insulin resistance and hyperlipidemia. Non-alcoholic steatohepatitis (NASH) is the progressive form of liver injury with the risk for progressive fibrosis, cirrhosis and end-stage liver disease. The pathophysiology that leads to NAFLD and NASH is not well understood. We hypo...

ea0013p171 | Diabetes, metabolism and cardiovascular | SFEBES2007

Abdominal obesity is associated with a decreased hepatic mRNA expression of 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) in patients with non-alcoholic steatohepatitis (NASH)

Konopelska Sarah , Kienitz Tina , Pirlich Matthias , Bauditz Juergen , Stewart Paul M , Hughes Beverly , Lochs Herbert , Strasburger Christian J , Quinkler Marcus

Background: Non-alcoholic fatty liver disease (NAFLD) is recognized as common liver disorder that represents the hepatic manifestation of the metabolic syndrome including visceral obesity, type 2 diabetes, insulin resistance and hyperlipidemia. Non-alcoholic steatohepatitis (NASH) is the progressive form of liver injury with the risk for progressive fibrosis, cirrhosis and end-stage liver disease. The pathophysiology that leads to NAFLD and NASH is not well understood. We hypo...